Proteins: Selection, Synthesis, and Purification Strategies for
Optimizing Drug Discovery
Proteins: Selection, Synthesis, and Purification Strategies for
Optimizing Drug Discovery
Deborah L. Janssen, Janssen Consulting
Proteins: Selection, Synthesis, and Purification Strategies for
Optimizing Drug Discovery evaluates current efforts to commercialize
this valuable source of potential drug targets. Proteins provide the
critical link between genes and disease, and as such are the key to
understanding of basic biological processes including disease pathology,
diagnosis, and treatment.
Proteomics will undoubtedly have a profound impact on the drug discovery
and development process. The pervasiveness of protein function and their
potential for therapeutic intervention are attracting increasing
attention from the pharmaceutical and biotechnology industries.
Proteomics promises to yield drugs with reduced side effects and improve
clinical trial success— Novartis’ Gleevec and Genentech’s Herceptin
exemplify the emergence of proteins as viable drug target candidates.
Researchers have discovered many potential therapeutic targets, and
there are currently more than 700 products in various phases of
development.
However, translating the study of proteins into optimized drug targets
poses substantial challenges. Hundreds of thousands of potential new
protein targets have been identified, but the resources to effectively
validate them are lacking. This report covers emerging tools and
methods, and the companies supplying them, for protein production and
commercialization, and evaluates the key barriers to discovering and
developing novel proteins as drug targets, diagnostic and protein chip
applications, and vaccines.
Report #35
Publishing in January 2004 by Cambridge Healthtech, est. 100 pages.
Print $2,500.00
Single-site PDF $5,000.00
Enterprisewide PDF $7,500.00
Click title to purchase this report "Proteins:
Selection, Synthesis, and Purification Strategies for Optimizing Drug
Discovery"
Expert Contributors
Thomas J. Bronzert, Ciphergen Biosystems, Inc.; G. Steven Burrill,
Burrill & Company; Tauseef R. Butt, LifeSensors Inc.; Grant Cameron/
Lorna Watson/ Kevin Auton, NextGen Sciences Ltd.; The Center for
Eukaryotic Structural Genomics (CESG) Development Team; Lorin Charlton/
Ryan Leskiw, PENCE; Jonas Ekblom, SEQUENOM, Inc.; John Michnowicz/
Rudolf Grimm, Agilent Technologies; James L.; Hartley, NCI /NCI
Frederick Protein Expression Laboratory; Dave Hicks, Applied Biosystems;
Jingfang Ju, USA Cancer Research Institute; M. Walid Qoronfleh, Perbio
Sciences
About the Author
Deborah Janssen has over ten years experience in the pharmaceutical
industry, both as a researcher and, most recently, as the Senior Editor
of Genomics & Proteomics and Drug Discovery & Development for Reed
Business Information. Before her tenure at RBI, Deb spent eight years
first as a research pharmacologist with Abbott Laboratories where she
won the Drug Discovery Innovator Award and then as a research geneticist
for Pharmacia Corp. Ms. Janssen has published a variety of scientific
papers on such topics as the effects of rosiglitazone on glucose
transporter regulation, macrolide-based nonpeptide antagonists of GnRH,
and the in vivo blockade of dexamethasone-induced thymolysis in
adrenalectomized rats. Deb holds a Master’s degree in Cell and Molecular
Biology from Northeastern Illinois University and is a principal partner
with Janssen Consulting.
Click title to purchase this report "Proteins:
Selection, Synthesis, and Purification Strategies for Optimizing Drug
Discovery" "
Table of Contents
Chapter 1. Introduction and Overview
1.1 Why Study Proteomics?
-Scientific Overview
--Biomarkers on the Brain
1.2 The Significance of Protein Expression Studies
Chapter 2. Protein Expression and Purification Techniques
2.1 High-Throughput Protein Studies: The Ideal Situation
-Choosing an Expression Vector/Host: So Many Choices
-Strategies for Selection of Expression Systems
-Multiplicity Is What Works
-High-Throughput Cloning Techniques
--Making a Difference
-Purification, Parallel Processing, and Scale-Up
-A Processing Protease Solution
-A High-Throughput, Chip-Based Expression System
2.2 Protein Expression Strategies for Difficult-to-Express Proteins
-Refolding Methods
-Fusion Systems
-Ubiquitin Fusion Technology
-Rhodobacter sphaeroides Expression System for Membrane Proteins
-A Humanized Yeast Expression System
2.3 Examining Protein Variation: The Search for Therapeutic Proteins
-Phage Display Libraries and Techniques
-Discovering Compounds Through Phage Display
-Molecular Evolution Approaches
-Aptamers and Spiegelmers
Chapter 3. Business Considerations
Chapter 4. Expert Commentaries
Thomas J. Bronzert, Ciphergen Biosystems, Inc.
G. Steven Burrill, Burrill & Company
Tauseef R. Butt, LifeSensors Inc.
Grant Cameron/ Lorna Watson/ Kevin Auton, NextGen Sciences Ltd.
The Center for Eukaryotic Structural Genomics (CESG) Development Team
Lorin Charlton/ Ryan Leskiw, PENCE
Jonas Ekblom, SEQUENOM, Inc.
James L. Hartley, NCI /NCI Frederick Protein Expression Laboratory
Dave Hicks, Applied Biosystems
Jingfang Ju, USA Cancer Research Institute
John Michnowicz/ Rudolf Grimm, Agilent Technologies
M. Walid Qoronfleh, Perbio Sciences
Glossary
Company Index
Figures
Figure 1: Generation of ORF 1 and ORF 2 PCR Products
Figure 2: Novagen LIC Duet Adaptor Cloning
Figure 3: Expressionfactory™ Expression Host Systems
Figure 4: Expressionfactory™ Vector/Host Combinations
Figure 5: Trinity™ Suite of Expression Vectors
Figure 6: Subtilisin
Figure 7: The SELDI Process and ProteinChip® Arrays
Figure 8: LifeSensors’ Fusion Technology
Figure 9: Crystal Structure of Ubiquitin
Figure 10: Rhodobacter Expression System
Figure 11: Human IgG1 Protein
Figure 12: Pichia pastoris
Figure 13: Displayed Protein on Surface of Phage
Figure 14: Selection Scheme for Identifying Specific Peptides from Phage
Display Libraries
Click title to purchase this report "Proteins:
Selection, Synthesis, and Purification Strategies for Optimizing Drug
Discovery"
|
